Iwicki Mark T — SEC Form 4 filings
SEC reporting owner CIK 1415537. 26 Form 4 filings on record with FilingPulse; latest filed 2026-07-21.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-03-27 to 2026-07-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings — 218,192 shares, $420,941 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
- Largest priced transaction: sale of 154,894 shares @ $0.81 ($125,464) in KALA BIO, Inc., filed 2025-10-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | Director | 8 | — | 7 legs · 218,192 sh · $420,941 | 4 |
| Merus N.V. (MRUS) | Director | 3 | — | — | 12 |
| Akero Therapeutics, Inc. (AKRO) | Director | 3 | — | — | 11 |
| Q32 Bio Inc. (QTTB) | Director | 5 | — | — | 10 |
| Inhibikase Therapeutics, Inc. (IKT) | Chief Executive Officer, Director | 4 | — | — | 5 |
| Third Harmonic Bio, Inc. (THRD) | Director | 2 | — | — | 3 |
| Aerovate Therapeutics, Inc. (AVTE) | Director | 1 | — | — | 1 |
Form 4 filings — Iwicki Mark T
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-21 | 4/A | Q32 Bio Inc. (QTTB) | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Inhibikase Therapeutics, Inc. (IKT) | Grant/award (A): 4,982,706 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Merus N.V. (MRUS) | Code (U): 73,576 @ $97 · Disposition to issuer (D): 13,193 (derivative) @ $0 · Disposition to issuer (D): 8,844 (derivative) @ $0 · Disposition to issuer (D): 14,414 (derivative) @ $0 · Disposition to issuer (D): 16,604 (derivative) @ $0 · Disposition to issuer (D): 6,120 (derivative) @ $0 · +4 more | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) · +3 more | EDGAR |
| 2025-10-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-24 | 4 | KALA BIO, Inc. (KALA) | Sale (S): 154,894 @ $0.81 | EDGAR |
| 2025-08-14 | 4 | Third Harmonic Bio, Inc. (THRD) | Other (J): 128,631 · Other (J): 83,296 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4/A | Inhibikase Therapeutics, Inc. (IKT) | Grant/award (A): 602,346 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | KALA BIO, Inc. (KALA) | Sale (S): 13,227 @ $4.01 | EDGAR |
| 2025-06-17 | 4 | KALA BIO, Inc. (KALA) | Grant/award (A): 2,450 @ $0 · Grant/award (A): 5,450 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4/A | KALA BIO, Inc. (KALA) | Sale (S): 10,866 @ $3.74 | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2025-06-04 | 4 | KALA BIO, Inc. (KALA) | Sale (S): 10,866 @ $3.74 | EDGAR |
| 2025-05-27 | 4 | Merus N.V. (MRUS) | Grant/award (A): 13,193 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Q32 Bio Inc. (QTTB) | Disposition to issuer (D): 37,222 (derivative) @ $0 · Grant/award (A): 37,222 (derivative) @ $0 · Disposition to issuer (D): 7,615 (derivative) @ $0 · Grant/award (A): 7,615 (derivative) @ $0 · Disposition to issuer (D): 25,534 (derivative) @ $0 · Grant/award (A): 25,534 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | Inhibikase Therapeutics, Inc. (IKT) | Grant/award (A): 602,346 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Inhibikase Therapeutics, Inc. (IKT) | Grant/award (A): 4,373,857 (derivative) @ $0 · Grant/award (A): 1,794,291 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | KALA BIO, Inc. (KALA) | Grant/award (A): 22,100 @ $0 · Sale (S): 5,779 @ $7.63 · Grant/award (A): 99,500 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | KALA BIO, Inc. (KALA) | Sale (S): 15,168 @ $4.75 | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Third Harmonic Bio, Inc. (THRD) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | KALA BIO, Inc. (KALA) | Sale (S): 7,392 @ $6.09 | EDGAR |
| 2024-05-09 | 4 | Merus N.V. (MRUS) | Grant/award (A): 8,844 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 25,534 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1415537 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →